stars 1 stars 2 stars 3

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Metabiomics Questions

The Metabiomics annual revenue was $811000 in 2026.

Gregory Kuehn is the Vice President and Chief Operating Officer of Metabiomics.

5 people are employed at Metabiomics.

Metabiomics is based in Carlsbad, California.

The NAICS codes for Metabiomics are [54, 5417, 54171, 541, 541713].

The SIC codes for Metabiomics are [87, 873].

Top Metabiomics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users